ArticleTranslational vision science & technology2026
The Role of Dopaminergic Agonists in Geographic Atrophy: Converging Evidence From Clinical and Experimental Data.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Purpose: Levodopa (L-DOPA) is an emerging drug repurposing candidate for age-related macular degeneration (AMD). Basic and clinical studies identify a potential role for L-DOPA to prevent and treat neovascular AMD. However, only one prior study has been performed in geographic atrophy (GA). Methods: We performed a retrospective cohort analysis from the Sight Outcomes Research Collaborative database, including eyes with a diagnosis of early- or intermediate-stage AMD in 1 eye. We compared eyes exposed to any dopamine agonist (DA), dopamine receptor D2 agonist, and L-DOPA with eyes with no DA exposure using propensity score matching and survival analysis with multivariable Cox proportional hazard models with new GA development as our primary outcome. Mice were treated with intraperitoneal NaIO3 to induce GA-like pathology. We compared L-DOPA with phosphate-buffered saline-treated controls in both pigmented and albino mice. We quantified retinal thickness by optical coherence tomography, and performed immunofluorescence to quantify choriocapillaris and retinal pigment epithelium density. Results: Any DA, dopamine receptor D2, and L-DOPA exposure were not associated with new-onset GA. NaIO3 treatment caused retinal thinning, choriocapillaris loss, and retinal pigment epithelium degeneration, which were not rescued by L-DOPA treatment in pigmented nor albino mice. Conclusions: In both retrospective database analysis and preclinical models, DA had no effect upon GA pathology. Translational Relevance: Further investigation of levodopa may be more appropriately directed toward neovascular age-related macular degeneration, rather than geographic atrophy, where preclinical, retrospective, epidemiologic, and prospective data suggest a benefit.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.